EDT broadens its manufacturing focus

As we reported in August, Irish drugmaker Elan is not yet ready to spin off its drug delivery unit. Turns out, the drug delivery unit, EDT, is  broadening its manufacturing offerings. "While we have been 40 years manufacturing products for companies, it has almost exclusively been related to a drug delivery contract into which the parties have entered," spokeswoman Fidelma Callanan tells Outsourcing-pharma. "We want to extend this more to specialised manufacturing which is not necessarily tied to drug delivery contracts." Report

Note: This report was changed from an earlier version in which we said that Elan was moving away from drug delivery. Actually, it is the EDT unit that is broadening its focus. We apologize for the error.

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.